HFS
WST icon

Hantz Financial Services’s West Pharmaceutical WST Stock Holding History

Hantz Financial Services’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
964
+43
+5% +$13.1K ﹤0.01% 885
2026
Q1 		$231K Sell
921
-16
-2% -$3.98K ﹤0.01% 948
2025
Q4 		$258K Sell
937
-41
-4% -$11.2K ﹤0.01% 771
2025
Q3 		$256K Sell
978
-69
-7% -$16.8K ﹤0.01% 680
2025
Q2 		$229K Sell
1,047
-24,709
-96% -$5.28M ﹤0.01% 601
2025
Q1 		$5.77M Sell
25,756
-1,061
-4% -$292K 0.1% 192
2024
Q4 		$8.78M Buy
26,817
+490
+2% +$154K 0.15% 145
2024
Q3 		$7.9M Sell
26,327
-2,739
-9% -$839K 0.14% 173
2024
Q2 		$9.57M Sell
29,066
-1,287
-4% -$455K 0.18% 139
2024
Q1 		$12M Sell
30,353
-2,160
-7% -$799K 0.23% 114
2023
Q4 		$11.4M Sell
32,513
-1,240
-4% -$439K 0.25% 118
2023
Q3 		$12.7M Sell
33,753
-20
-0.1% -$7.73K 0.32% 88
2023
Q2 		$12.9M Buy
33,773
+851
+3% +$304K 0.32% 85
2023
Q1 		$11.4M Sell
32,922
-1,403
-4% -$410K 0.31% 88
2022
Q4 		$8.08M Sell
34,325
-2,473
-7% -$586K 0.24% 130
2022
Q3 		$9.05M Buy
36,798
+1,161
+3% +$354K 0.31% 97
2022
Q2 		$10.8M Buy
35,637
+524
+1% +$171K 0.36% 80
2022
Q1 		$14.4M Buy
35,113
+2,136
+6% +$836K 0.43% 59
2021
Q4 		$15.5M Buy
32,977
+2,082
+7% +$896K 0.45% 60
2021
Q3 		$13.1M Buy
30,895
+3,766
+14% +$1.59M 0.43% 66
2021
Q2 		$9.74M Buy
27,129
+1,372
+5% +$453K 0.36% 75
2021
Q1 		$7.26M Buy
25,757
+1,393
+6% +$399K 0.3% 92
2020
Q4 		$6.9M Buy
24,364
+641
+3% +$180K 0.31% 93
2020
Q3 		$6.52M Buy
23,723
+541
+2% +$143K 0.33% 80
2020
Q2 		$5.27M Buy
+23,182
New +$4.55M 0.29% 101

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hantz Financial Services's WST Position: Q2 2026 in Review

Hantz Financial Services increased its West Pharmaceutical (WST) stake by 4.7% in Q2 2026, buying an estimated $13.1K and bringing the position to 964 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #885.

Hantz Financial Services first reported a position in WST in Q2 2020 and has held it in 25 quarters since. The position peaked at $15.5M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Hantz Financial Services held 964 shares of West Pharmaceutical worth $346K as of Q2 2026.
  • Hantz Financial Services bought 43 West Pharmaceutical shares in Q2 2026, an estimated $13.1K.
  • West Pharmaceutical made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #885 holding.
  • Hantz Financial Services first reported a position in West Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • Hantz Financial Services's West Pharmaceutical position peaked at $15.5M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.